TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15165758

Group type: EXPERIMENTAL
Intervention: Active SLE
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Highly active SLE
Number of subjects: 98

Group type: COMPARATOR
Intervention: Inactive SLE
Number of subjects: 98

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 98
Study: 12226035

Group type: EXPERIMENTAL
Intervention: Ribavirin treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 49
Study: 9215181

Group type: EXPERIMENTAL
Intervention: Spontaneous placental removal
Number of subjects: 333

Group type: COMPARATOR
Intervention: Manual placental removal
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Spontaneous placental removal (subset analysis with ruptured membranes)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Manual placental removal (subset analysis with ruptured membranes)
Number of subjects: 333
Study: 7696831

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 3667068

Group type: EXPERIMENTAL
Intervention: Diet + Exercise (DE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 12
Study: 31738736

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (1,000 mg daily for 8 weeks)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo (matching capsules for 8 weeks)
Number of subjects: 189
Study: 29621261

Group type: EXPERIMENTAL
Intervention: GOT+IOT
Number of subjects: 129
Study: 28636184

Group type: EXPERIMENTAL
Intervention: Bococizumab (150 mg subcutaneously) administered to the abdomen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bococizumab (150 mg subcutaneously) administered to the thigh
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bococizumab (150 mg subcutaneously) administered to the upper arm
Number of subjects: 75
Study: 25399048

Group type: EXPERIMENTAL
Intervention: NEMEX therapy twice a week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Optimized analgesics and antiinflammatory drug use (acetaminophen and oral NSAIDs)
Number of subjects: 100
Study: 23246422

Group type: COMPARATOR
Intervention: Placebo spray (Lidocaine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neomycin‐Bacitracin combination spray
Number of subjects: 90
Study: 20345827

Group type: EXPERIMENTAL
Intervention: Tailored web-based educational intervention based on Transtheoretical Model concepts
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard intervention (standardised mammography brochures)
Number of subjects: 128
Study: 18926436

Group type: EXPERIMENTAL
Intervention: Medical management (MM)
Number of subjects: 47
Study: 16818923

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with olive oil
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with nuts
Number of subjects: 772

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 772
Study: 12714786

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg/m(2) orally)
Number of subjects: 56
Study: 11020672

Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration with additional support at sacral level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration with additional support at shoulder level
Number of subjects: 0

Group type: COMPARATOR
Intervention: Achilles tendon vibration without additional support
Number of subjects: 0
Study: 8820004

Group type: EXPERIMENTAL
Intervention: Brodimoprim 200 mg tablets, single dose of two 200 mg tablets on day 1, followed by one tablet per day on days 2 and 3 (58 patients)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Brodimoprim 200 mg tablets, single daily dose of two tablets for 2 days (63 patients)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Pefloxacin, single dose of two 400 mg tablets for 1 day (51 patients)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: All groups (Brodimoprim and Pefloxacin)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Brodimoprim for 2 days
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Brodimoprim for 3 days
Number of subjects: 172

Group type: COMPARATOR
Intervention: Pefloxacin
Number of subjects: 172
Study: 7524696

Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion
Number of subjects: 20
Study: 3555589

Group type: EXPERIMENTAL
Intervention: Captopril plus hydrochlorothiazide (HCTZ)
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Perceived best therapy
Number of subjects: 2128
Study: 29759943

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 27
Study: 28711750

Group type: EXPERIMENTAL
Intervention: ENCOURAGE program (12-week access)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study: 24290414

Group type: EXPERIMENTAL
Intervention: Losartan/hydrochlorothiazide 50 + 12.5 mg tablet (EPR0001)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preminent® reference formulation of losartan/hydrochlorothiazide 50 + 12.5 mg tablet
Number of subjects: 0
Study: 23031421

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 20795844

Group type: EXPERIMENTAL
Intervention: Charcoal cookie (3 cookies, equivalent to 7.2 g of charcoal)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aqueous activated charcoal suspension (7.2 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Palatability of charcoal cookie
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Palatability of aqueous activated charcoal suspension
Number of subjects: 8
Study: 18187995

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alfentanil and sodium nitroprusside
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 15789393

Group type: EXPERIMENTAL
Intervention: Outpatient management (transradial PTCA)
Number of subjects: 644

Group type: COMPARATOR
Intervention: In-hospital management (transfemoral PTCA)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Transfemoral PTCA
Number of subjects: 644
Study: 11886970

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg intramuscular injections weekly
Number of subjects: 174

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM) 50 mg intramuscular injections weekly
Number of subjects: 174
Study: 9701861

Group type: EXPERIMENTAL
Intervention: Stress-management training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 0
Study: 7995691

Group type: EXPERIMENTAL
Intervention: e‐PTFE membranes plus bone‐chip autografts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: e‐PTFE membranes plus demineralized freeze‐dried bone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: e‐PTFE membranes plus a new form of demineralized allograft bone tissue
Number of subjects: 0

Group type: COMPARATOR
Intervention: e‐PTFE membranes alone
Number of subjects: 0
Study: 3287737

Group type: EXPERIMENTAL
Intervention: Norfenefrine 15-30 mg t.i.d. for 6 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Norfenefrine in patients with most severe incontinence
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study: 29232576

Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU)
Number of subjects: 66
Study: 28885236

Group type: EXPERIMENTAL
Intervention: Conductive education (CE) approach added to conventional physiotherapy
Number of subjects: 17
Study: 26607233

Group type: EXPERIMENTAL
Intervention: Emotional wording in patient queries
Number of subjects: 117

Group type: COMPARATOR
Intervention: Scientific wording in patient queries
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Biomedical concept of medical experts
Number of subjects: 117
Study: 22704868

Group type: COMPARATOR
Intervention: Intermittent claudication
Number of subjects: 7403

Group type: EXPERIMENTAL
Intervention: Angina
Number of subjects: 7403

Group type: EXPERIMENTAL
Intervention: Both conditions (angina and intermittent claudication)
Number of subjects: 7403
Study: 21509327

Group type: EXPERIMENTAL
Intervention: Delayed school starting time by one hour (experimental group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Regular school schedule (control group)
Number of subjects: 47
Study: 18713456

Group type: EXPERIMENTAL
Intervention: Indinavir (IDV) 800 mg q8h for 3 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Indinavir (IDV) 800 mg q8h for 3 days and then IDV and American ginseng (AG) 1g q8h for 14 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Indinavir (IDV) alone
Number of subjects: 13
Study: 17347121

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Minimal control condition
Number of subjects: 31
Study: 12675761

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with hypertonic saline, 3 times daily for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with hypertonic saline
Number of subjects: 20

Group type: COMPARATOR
Intervention: No nasal irrigation (Control)
Number of subjects: 20
Study: 11028146

Group type: EXPERIMENTAL
Intervention: References to journal articles
Number of subjects: 24913

Group type: EXPERIMENTAL
Intervention: References to studies that were journal articles
Number of subjects: 24913

Group type: COMPARATOR
Intervention: Other references in this category
Number of subjects: 24913
Study: 9117013

Group type: EXPERIMENTAL
Intervention: Experimental rhinovirus 16 (RV16) infection (n = 7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (diluent) (n = 6)
Number of subjects: 13
Study: 1302564

Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 208

Group type: COMPARATOR
Intervention: Hernias diagnosis
Number of subjects: 208

Group type: COMPARATOR
Intervention: Heart disorders
Number of subjects: 208
Study: 3000923

Group type: EXPERIMENTAL
Intervention: Polyvalent intravenous immune globulin (20 cc/kg weekly doses before and after transplantation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus-specific hyperimmune globulin (5 cc/kg dose)
Number of subjects: 75
Study: 30661019

Group type: EXPERIMENTAL
Intervention: Early specialist palliative care (SPC)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 174
Study: 30019993

Group type: EXPERIMENTAL
Intervention: Intraarterial selective cooling infusion (IA‐SCI) with 350 ml 0.9% saline at 4℃ for 15 min
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no IA‐SCI)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intraarterial selective cooling infusion (IA‐SCI) with mechanical thrombectomy (MT)
Number of subjects: 113
Study: 27033961

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections (CSI), consisting of 3 injections over 12 months.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Physical therapy (PT), consisting of 8-12 sessions over 12 months.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both groups will receive instruction on recommended exercise and weight control strategies plus usual medical care.
Number of subjects: 156
Study: 23482922

Group type: EXPERIMENTAL
Intervention: Coach-led exercise training programme
Number of subjects: 1564
Study: 22491790

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus monitoring of mental state
Number of subjects: 288

Group type: COMPARATOR
Intervention: Monitoring of mental state only
Number of subjects: 288
Study: 20436446

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20‐40 mg/day for at least 3 months and Tizanidine 4‐8 mg/day for at least 2 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: Therapeutic blockades of the occipital nerve and trigger points using local anesthetics (2.5 ml of 0.5% marcain solution and 0.5‐1 ml dexazone, for 1‐5 blockades) and needle reflexotherapy
Number of subjects: 138
Study: 17028904

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 micrograms every 6 hours, maximum three doses)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Intravaginal prostaglandin E2 (3 mg every 6 hours, maximum three doses)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol and PGE(2)
Number of subjects: 415
Study: 16221261

Group type: COMPARATOR
Intervention: Atrial therapies programmed off
Number of subjects: 118
Study: 12017400

Group type: EXPERIMENTAL
Intervention: Inhaled insulin regimen (preprandial inhaled intrapulmonary insulin plus a single bedtime Ultralente injection)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Subcutaneous insulin regimen (split/mixed insulin with 2 to 3 injections daily)
Number of subjects: 51
Study: 10524386

Group type: EXPERIMENTAL
Intervention: Milk-supplemented group (3 servings of nonfat or 1% milk per day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (maintained usual diet)
Number of subjects: 204
Study: 7794582

Group type: EXPERIMENTAL
Intervention: Troglitazone 200 mg twice a day for 8 weeks
Number of subjects: 18
Study: 1797033

Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7037183

Group type: EXPERIMENTAL
Intervention: 30 mg of quazepam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31390072

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 111
Study: 28276596

Group type: EXPERIMENTAL
Intervention: 3750 IU/day of vitamin D3
Number of subjects: 257

Group type: COMPARATOR
Intervention: 600 IU/day of vitamin D3
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Both doses of vitamin D3
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: High-dose group (3750 IU/day)
Number of subjects: 257
Study: 26378683

Group type: EXPERIMENTAL
Intervention: Sequential Nephron Blockade (SNB)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Sequential Renin-Angiotensin System Blockade (SRASB)
Number of subjects: 164
Study: 24738239

Group type: EXPERIMENTAL
Intervention: Synbiotic drink containing a probiotic strain of bifidobacteria and Fucus evanescens polysaccharides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapy with inclusion of sour milk bifidobacterin
Number of subjects: 0
Study: 20946060

Group type: EXPERIMENTAL
Intervention: Anodic tDCS over Wernicke's area (20 min, 1 mA) in healthy individuals
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Anodic tDCS over Wernicke's area (20 min, 1 mA) in aphasic patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham stimulation in healthy individuals
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham stimulation in aphasic patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Anodic tDCS in aphasic patients (follow-ups at 1 and 3 weeks)
Number of subjects: 13
Study: 19261235

Group type: EXPERIMENTAL
Intervention: Sertraline (Zoloft), Naltrexone (Revia), and compliance enhancement therapy
Number of subjects: 74
Study: 16445970

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Memantine 0 mg daily (control)
Number of subjects: 8
Study: 15542366

Group type: EXPERIMENTAL
Intervention: Combined UVB, UVA and VIS light (mUV/VIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UVA and VIS irradiation
Number of subjects: 0
Study: 11320951

Group type: EXPERIMENTAL
Intervention: Early introduction of complementary foods (at 3 to 4 months of age)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Late introduction of complementary foods (at 6 months of age)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Both groups (early and late introduction)
Number of subjects: 175
Study: 9287228

Group type: EXPERIMENTAL
Intervention: Indinavir (800 mg every eight hours)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Zidovudine (200 mg every eight hours) and Lamivudine (150 mg twice daily)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Indinavir, Zidovudine, and Lamivudine (three-drug combination)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Indinavir (800 mg every eight hours) and Zidovudine-Lamivudine (200 mg and 150 mg respectively)
Number of subjects: 97
Study: 8296259

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms inhaled)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3090216

Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition (CEN) with an elemental formula
Number of subjects: 13

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: D‐xylose absorption
Number of subjects: 13
Study: 31413164

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis/conjunctivitis (ARC)
Number of subjects: 782320

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 782320

Group type: EXPERIMENTAL
Intervention: Atopic eczema (AE)
Number of subjects: 782320

Group type: COMPARATOR
Intervention: Control group (no documented allergic diseases)
Number of subjects: 782320
Study: 28946516

Group type: EXPERIMENTAL
Intervention: Stabilization exercise group (Group 1; n=18)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Home-exercise group (Group 2; n=16)
Number of subjects: 32
Study: 26848517

Group type: EXPERIMENTAL
Intervention: Guided seven‐week online Acceptance and Commitment Therapy (iACT) intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waiting list control condition (WLC)
Number of subjects: 68
Study: 23918445

Group type: EXPERIMENTAL
Intervention: Educational video 'Smart Hockey: More Safety, More Fun'
Number of subjects: 267

Group type: COMPARATOR
Intervention: No video (control group)
Number of subjects: 267
Study: 22210472

Group type: EXPERIMENTAL
Intervention: Active recovery (12 minutes of submaximal running and 8 minutes of static stretching)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Passive recovery (20 minutes sit on a bench)
Number of subjects: 31
Study: 21137291

Group type: EXPERIMENTAL
Intervention: Curving sheath‐needle multi‐direction rotating injection (CSNMRI) with ozone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional injection method with ozone
Number of subjects: 100
Study: 17331708

Group type: EXPERIMENTAL
Intervention: Formulation with medium chain triglycerides (MG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation with isopropyl myristate (IPM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation with light liquid paraffin (LP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo assessment
Number of subjects: 0
Study: 16494042

Group type: EXPERIMENTAL
Intervention: Experiment group (nonspeakers)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Contrasted group (speakers)
Number of subjects: 33
Study: 12136372

Group type: EXPERIMENTAL
Intervention: HRT containing 2 mg estradiol valerate and 250 microg levonorgestrel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10652728

Group type: EXPERIMENTAL
Intervention: 9 MIU (33 micrograms) of n‐hIFN beta by subcutaneous route, three times per week, on alternate days, during one year
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment for the first 6 months, then switched to n‐hIFN beta treatment for the following 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (after switching to treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 MIU (22 micrograms) of n‐hIFN beta once a week for 12 additional months
Number of subjects: 60
Study: 8682010

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 2096405

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine 48 mg/70 kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine 96 mg/70 kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 282906

Group type: EXPERIMENTAL
Intervention: Early splenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclic administration of arabinosyl cytosine and vincristine plus prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclic administration of arabinosyl cytosine plus thioguanine plus daunomycin
Number of subjects: 0
Study: 30675985

Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 86
Study: 28890309

Group type: EXPERIMENTAL
Intervention: Nitrous oxide - oxygen (60%-40%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oxygen 100%
Number of subjects: 40
Study: 26385957

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 19083

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19083
Study: 23600719

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% ointment
Number of subjects: 141

Group type: COMPARATOR
Intervention: Human breast milk
Number of subjects: 141
Study: 21681619

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived stem cell (BMC) therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 18496303

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg at induction with morphine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Morphine only (Control)
Number of subjects: 84
Study: 16275797

Group type: EXPERIMENTAL
Intervention: Antiviral therapy (amantadine hydrochloride or oseltamivir phosphate)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 3

Group type: COMPARATOR
Intervention: Rapid testing
Number of subjects: 3
Study: 12384195

Group type: EXPERIMENTAL
Intervention: Cash payment (HKD $10, $20, $40)
Number of subjects: 4850

Group type: EXPERIMENTAL
Intervention: Lottery entry (HKD $1,000, $2,000, $4,000)
Number of subjects: 4850

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 4850

Group type: EXPERIMENTAL
Intervention: First mailing
Number of subjects: 4850

Group type: EXPERIMENTAL
Intervention: Second mailing
Number of subjects: 4850